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Hereditary Hemochromatosis: Genetic
Complexity and New Diagnostic Approaches
Dorine W. Swinkels,1* Mirian C.H. Janssen,2 Ju¨rgen Bergmans,1 and
Joannes J.M. Marx1,3
Since the discovery of the hemochromatosis gene (HFE)
in 1996, several novel gene defects have been detected,
explaining the mechanism and diversity of iron-over-
load diseases. At least 4 main types of hereditary hemo-
chromatosis (HH) have been identified. Surprisingly,
genes involved in HH encode for proteins that all affect
pathways centered around liver hepcidin synthesis and
its interaction with ferroportin, an iron exporter in
enterocytes and macrophages. Hepcidin concentrations
in urine negatively correlate with the severity of HH.
Cytokine-mediated increases in hepcidin appear to be
an important causative factor in anemia of inflamma-
tion, which is characterized by sequestration of iron in
the macrophage system. For clinicians, the challenge is
now to diagnose HH before irreversible damage devel-
ops and, at the same time, to distinguish progressive
iron overload from increasingly common diseases with
only moderately increased body iron stores, such as the
metabolic syndrome. Understanding the molecular reg-
ulation of iron homeostasis may be helpful in designing
innovative and reliable DNA and protein tests for
diagnosis. Subsequently, evidence-based diagnostic
strategies must be developed, using both conventional
and innovative laboratory tests, to differentiate between
the various causes of distortions of iron metabolism.
This review describes new insights in mechanisms of
iron overload, which are needed to understand new
developments in diagnostic medicine.
© 2006 American Association for Clinical Chemistry
Iron is involved in the function of all cells. It is able to
accept and donate electrons, depending on its oxidation
state: ferrous iron [Fe(II)] or ferric iron [Fe(III)]. This
ability is crucial for the function of oxygen-binding mol-
ecules, mainly hemoglobin and myoglobin, and iron-
containing enzymes, including the cytochrome system in
mitochondria. Iron is mostly locked into iron protopor-
phyrin (heme) and iron–sulfur clusters, which serve as
enzyme cofactors. Without iron, cells lose their capacity
for electron transport and energy metabolism. However,
iron can also cause damage, because Fe(II) catalyzes the
generation of highly reactive hydroxyl radicals (·OH)
from hydrogen peroxide (H2O2), which is called the
Fenton reaction (1 ). These hydroxyl radicals damage
cellular membranes, proteins, and DNA. A large number
of scavenger molecules protect cells against iron-medi-
ated tissue damage. Proteins sequester iron to reduce this
threat. Iron circulates bound to plasma transferrin, which
is needed to offer the highly insoluble Fe(III) to cells via
the transferrin receptor (TfR).4 Iron can safely be stored
within cells in the form of ferritin and hemosiderin
[reviewed in Ref. (2 )]. Usually, only small amounts of iron
exist outside this physiologic sink, although stored iron
can be mobilized for reuse. Many diseases arise from
imbalances in iron homeostasis. Too much iron accumu-
lates in hereditary hemochromatosis (HH), porphyria
cutanea tarda, and the iron-loading anemias (hemolytic,
dyserythropoietic, myodysplastic, and aplastic anemias),
which are often aggravated by multiple transfusions. In
iron-deficiency anemia (IDA), insufficient amounts of iron
are available for heme synthesis. In anemia of inflamma-
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tion (AI), iron is redistributed to macrophages to promote
resistance to infections (3 ).
The control of iron homeostasis acts at both the cellular
and the systemic level and involves a complex system of
different cell types, transporters, and signals. To maintain
systemic iron homeostasis, communication between cells
that absorb iron from the diet (duodenal enterocytes),
consume iron (mainly erythroid precursors), and store
iron (hepatocytes and tissue macrophages) must be
tightly regulated. The recently identified -defensin-like
antimicrobial peptide hepcidin is thought to be the long-
anticipated regulator that controls iron absorption and
macrophage iron release. Hepcidin is synthesized in the
liver when changes occur in body iron needs, such as in
anemia, hypoxia, and inflammation, and is secreted in the
circulation. Recently, light was also shed on how hepcidin
exerts this regulatory function; it was reported to coun-
teract the function of ferroportin, a major cellular iron-
exporter protein in the membranes of macrophages and
the basolateral site of enterocytes, by inducing its inter-
nalization and degradation (4–6).
Background information on these major pathways of
iron exchange and the role of hepcidin in iron regulation
is provided in Fig. 1, and Fig. 2 displays key sites in iron
homeostasis in more detail. Also shown in Figs. 1 and 2
are the many proteins involved in iron metabolism. Most
of these proteins have been identified during the last few
years, during which molecular genetics have added sub-
stantially to the understanding of iron metabolism [see
Refs. (7–16) and the reviews in Refs. (17–19)]. Since the
discovery of the hemochromatosis gene (HFE)5 in 1996,
the identification of numerous additional genes that are
mutated in genetic hemochromatosis has revolutionized
the diagnosis of primary iron overload by introducing
molecular and protein tests that allow early, presymptom-
atic, accurate diagnosis. However, many links are still
incomplete, leaving even more intriguing questions. In
this review, we summarize the major advances from the
5 Human genes: HFE, hemochromatosis; HJV (alias, HFE2), hemochroma-
tosis type 2 (juvenile); HAMP, hepcidin antimicrobial peptide (alias, LEAP-1);
SMAD4, mothers against DPP homolog 4 (Drosophila); TfR2, transferrin recep-
tor 2 (alias, HFE3); SLC40A1, solute carrier family 40 (iron-regulated trans-
porter), member 1 (aliases, IREG1, FPN1, HFE4); FTL, L-ferritin; and SLC11A2,
solute carrier family 11 (proton-coupled divalent metal ion transporters),
member 2 (aliases, DMT1, DCT1, and NRAMP2).
Fig. 1. Pathways of iron exchange.
The largest flux of iron takes place in the recycling of iron from senescent erythrocytes out of macrophages to incorporation in erythroid precursors. Note that values
for the different tissues and fluxes are approximate. The liver and reticuloendothelial macrophages function as major iron stores. Only 1–2 mg of iron is absorbed and
lost every day. Importantly, the total amount of iron in the body can be regulated only by absorption, whereas iron loss occurs only passively from sloughing of skin
and mucosal cells as well as from blood loss. Hepcidin, a recently identified, antimicrobial, -defensin-like peptide secreted by the liver, controls the plasma iron
concentration by inhibiting iron export by ferroportin from duodenal enterocytes and reticuloendothelial macrophages [see also Fig. 1 of Ref. (4 )]. As a consequence,
an increase in hepcidin production leads to a decrease in plasma iron concentrations (92, 200). Hepcidin expression is regulated by iron concentrations in hepatocytes,
by inflammatory stimuli, by erythroid iron demand, and by hypoxia via pathways involving expression of the HFE, TRF2, and HJV genes (Fig. 2D)
(16, 82, 84, 89, 90, 104, 174, 175). In HFE-, TfR2-, and HJV-related HH, hepcidin production is low despite increased liver iron, leading to inappropriately increased
iron absorption (16, 104, 175). A, B, C, and D refer to sites with special functions in iron metabolism as depicted in Fig. 2. sHJV, soluble HJV.
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Fig. 2. Key sites of iron metabolism.
There are 4 sites with special functions in iron handling: enterocytes (A), erythroid precursors (B), macrophages (C), and hepatocytes (D). (A), enterocyte. Iron in food
can be present in an inorganic form (Fe3) or as hemoglobin or myoglobin. Fe3 in soluble iron complexes is reduced to Fe2 by DcytB in the brush border and is
transported into the duodenal enterocytes by DMT1. Heme enters the enterocyte after enzymatic digestion of hemoglobin and myoglobin, presumably through a heme
cell transport protein, HCP1 (166). Within the enterocyte, heme is degraded by heme oxygenase (HO), and Fe2 iron is released. From there, iron is either stored as
ferritin or transported across the basolateral membrane to enter the circulation. This transport across the basolateral membrane is mediated by the iron transporter
ferroportin, which transports Fe2 to the plasma, where it is oxidized to Fe3 by hephaestin, a membrane-resident multicopper oxidase very similar to ceruloplasmin
(Cp), facilitating binding to transferrin (Tf). Evidence is accumulating that the peptide hormone hepcidin inhibits ferroportin function (4 ). Consequently, in case of high
plasma hepcidin concentrations, most iron absorbed by the enterocyte is trapped as ferritin and lost in the feces. (B), erythroid precursor. Erythroid precursors take
up iron through the transferrin cycle. Transferrin binds to TfR1 on the cell surface. The complexes localize to clathrin-coated pits, which invaginate to initiate endocytosis.
In specialized endosomes, a decrease in pH induces the release of iron from transferrin. Fe3 is converted to Fe2, presumably by STEAP3 (168), which enables iron
transport out of the endosomes via DMT1. Subsequently, apotransferrin (apo-Tf) and the TfR1 both return to the cell surface. Both proteins participate in further rounds
of iron delivery. Iron is transported mainly into mitochondria for incorporation into heme and Fe-S proteins. Excess iron is stored as ferritin and hemosiderin. In erythroid
cells, essentially all iron is incorporated into hemoglobin. (C), macrophage. Reticuloendothelial macrophages carry out iron recycling. They ingest senescent
erythrocytes and lyse them in a phagolysosomal compartment. Hemoglobin (Hb) is degraded, and iron is liberated from heme. The enzyme heme oxygenase (HO)
participates in this process. Iron is then either stored as ferritin or exported out of the cell by ferroportin and ceruloplasmin (Cp). A considerable amount of iron is
released as ferritin or hemoglobin (201). (D), hepatocyte. Hepatocytes take up iron through multiple pathways. The molecules involved in transport of NTBI, hemoglobin
(Hb), heme (Haem), and ferritin have not yet been identified. As in macrophages, iron in hepatocytes is either stored as ferritin and hemosiderin or exported out of the
cell by ferroportin and subsequently oxidized by ceruloplasmin (Cp) before binding to transferrin (Tf). Available data do suggest that HFE in interaction with TfR1 and
parallel to TfR2 is implicated in the iron-sensing pathway of hepatocytes that controls hepcidin synthesis (84). A GPI-linked cell-associated HJV may interact with the
transmembrane neogenin receptor to induce changes in hepcidin synthesis in the hepatocyte. A soluble circulating form of HJV (sHJV) derived from skeletal muscle is
hypothesized to serve as an antagonist to disrupt these interactions (89, 90). Knowledge on the cellular processes regulating this hepcidin production and secretion in the
hepatocyte is limited. The hepcidin gene (HAMP), located on chromosome 19q13.1, encodes a precursor protein of 84 amino acids. The production and localization of
pre-prohepcidin in hepatocytes is assumed to be intracellular in the secretory pathway (202). During its export from the cytoplasm, this full-length pre-prohepcidin undergoes
enzymatic cleavage of a 24-amino acid amino-terminal endoplasmic reticulum–targeting signal peptide, producing a 60-amino acid prohepcidin peptide (190,203). Next, the
35-amino acid proregion peptide is removed by a furin-like proprotein convertase (14, 204), most likely in the trans-Golgi network, producing mature hepcidin (25-amino acid
form), which can be purified from human blood ultrafiltrate (171). Question marks indicate that either the pathway or the transport has not been elucidated.
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molecular studies of iron overload in the light of their
relevance to the understanding and design of diagnostic
strategies for defects in iron regulatory pathways.
Hereditary Hemochromatosis
Iron-overload disease can be primary (hereditary) or
secondary (inborn or acquired) (20 ). The latter disorders
have in common the fact that the patient is anemic (Table
1). When anemia is accompanied by increased erythroid
activity and/or ineffective erythropoiesis, e.g., in case of
thalassemia and sideroblastic anemia, congenital dyser-
ythropoietic anemia, and some myelodysplastic disor-
ders, there is an appropriately increased absorption of
iron from the diet because of higher needs of iron for
hemoglobin synthesis (20, 21). These patients develop
iron overload even without transfusions of erythrocytes.
If transfusions are needed, they will add to the body iron
excess. Primary causes of hemochromatosis usually stem
from inherited abnormalities of proteins implicated in
iron transport and regulation that may lead to excessive
absorption of iron from the gastrointestinal tract. The
disease was first described at the end of the 19th century
by von Recklinghausen, but also by Trousseau and Troi-
sier. It was von Recklinghausen who originally intro-
duced the term hemochromatosis. In 1935, Sheldon wrote
his classic review in which hemochromatosis was re-
garded as a very rare disease that results from excess total
body iron and organ failure attributable to iron toxicity
(22 ). By the 1980s, a higher prevalence was suggested,
probably because of the widespread availability of serum
iron, iron-binding capacity, and ferritin assays by that
time. In the 1970s, hemochromatosis was recognized as an
autosomal recessive disorder linked to the short arm of
chromosome 6, which contains the gene that encodes
HLA-A (23 ). However, it was only in 1996, that Feder et
al. (7 ) identified the hemochromatosis (HFE) gene (previ-
ously called HLA-H gene). These authors attributed the
most common form of hereditary hemochromatosis (HH)
to homozygosity for the C282Y sequence variation of this
gene. The so calledHFE-related HH is characterized by an
increase in iron absorption inappropriate to body iron
stores, which leads to iron deposition in parenchymal
organs such as the liver and the pancreas. Initial clinical
symptoms of tissue iron overload typically occur at adult
age and are often nonspecific and vague. In later stages,
disease manifestations may include arthropathy, diabetes
mellitus, hypogonadism and other endocrinopathies, liver
cirrhosis, cardiomyopathy, skin pigmentation, and in cir-
rhotic patients, increased susceptibility to liver cancer
(24–35). Early diagnosis and therapeutic phlebotomy can
prevent the development of tissue damage, reducing
morbidity and mortality and providing long-term sur-
vival similar to the general population (25, 26, 31, 33,
34, 36–38).
The identification of the HFE gene was the start of
rapid advances in the understanding of iron homeostasis.
It has since become obvious that other genetic entities can
cause clinical pictures identical to that of the HFE gene
defect [reviewed in Ref. (19 )]. On the other hand, some of
these new gene abnormalities are associated with mark-
edly different clinical and biochemical pictures of iron
overload. The large number of genes in which sequence
variants are associated with iron overload complicates the
diagnostic approach. Unfortunately, an increasing num-
ber of patients undergo molecular testing just because
plasma ferritin and transferrin saturation (TS) are in-
creased. Often this leads to an unnecessary search for
hereditary defects in individuals with various common,
nonhereditary conditions that are characterized by similar
abnormalities in serum ferritin and/or TS, such as hepa-
titis, excessive alcohol consumption, several conditions
co-occurring in the metabolic syndrome [glucose intoler-
ance, obesity, hypertension (39 )], and secondary forms of
iron overload (2, 20, 21, 25, 40–54) (Table 1 and Fig. 3).
Furthermore, without a well-defined indication, molecu-
Table 1. Differential diagnosis of iron overload in humans.
Hereditary hemochromatosis
HFE-associated HH (type 1) (7 )
C282Y homozygosity
C282Y/H63D compound heterozygosity
Non-HFE-associated HH
Type 2A HJV variants (16)
Type 2B hepcidin variants (15)
Type 3 TfR variants (9 )
Type 4 ferroportin variants (11)
Other
HHCS (133–135, 162)
Heme oxygenase deficiency (205)
Neonatal iron overload (206)
Aceruloplasminemia (119, 136)
Congenital atransferrinemia or hypotransferrinemia (160, 161)
DMT1 variants (163)
Secondary iron overload
Iron-loading anemias (20, 21)
Ineffective erythropoiesis
Thalassemic syndromes
Sideroblastic anemia
Myelodysplastic syndrome
Congenital dyserythropoiesis
Increased erythropoiesis
Chronic hemolytic anemia
Parenteral iron overload (including multiple blood transfusions)
Other
Metabolic syndrome (43, 50)
Obesity (42, 47, 54)
Hypertension (48)
Insulin resistance (49–52)
Chronic liver disease
Hepatitis (193, 194)
Alcohol abuse (45)
Nonalcoholic steatohepatitis (44)
Porphyria cutanea tarda (207)
Iron overload in sub-Saharan Africa (118–120)
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Fig. 3. Flow chart proposed for the diagnosis of
the various forms of HH.
The diagram includes innovative molecular, hepcidin,
and magnetic resonance imaging (MRI) tests. Future
studies are needed to collect evidence to validate this
flow chart. Except for the information included in this
diagram, rational gene targeting is also based on
information on clinical presentation, hemoglobin (low
in secondary forms of iron overload and in some cases
with ferroportin disease), family history (hereditary
disease), concomitant diseases (e.g., hepatitis and
alcohol abuse), and age at presentation (young age in
juvenile forms of HH) (53). HH types 1–4 refer to the
OMIM classification (Table 2). ALT, alanine amino-
transferase; AST, aspartate aminotransferase.
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lar diagnostics carry the risk of detecting abnormalities in
genes of which the clinical consequence in time is un-
known at present.
Currently there are 5 major forms of HH, each caused
by sequence variations in a different gene (Table 2).
Classic Hemochromatosis: The HFE Gene
The C282Y sequence variant may have originated in a
single Celtic ancestor in northern Europe approximately
2000 years ago (55 ). Rapid dissemination of this C282Y
sequence variant has subsequently caused HH to be one
of the most common inherited disorders in the Caucasian
population of northern European descent, with a carrier
frequency of the main C282Y sequence variant of 1 in 10
and homozygosity in 1 in 200. Apparently this genetic
defect has no negative adverse consequences for repro-
duction. It may even have conferred some advantages, for
which 2 main hypotheses have been proposed. The first
has been mentioned frequently and is based on the lower
prevalence of iron deficiency and a subsequent positive
effect on the reproduction of young C282Y heterozygous
women in ancient times, when dietary iron was scarce
(56 ). To date, however, evidence is lacking that the
presence of HFE sequence variants also protects against
(iron deficiency) anemia (57 ). An alternative hypothesis is
based on a protective effect against some pathologic
agents. This can be related to the HFE protein as a
cell-surface receptor for some infectious agents (58 ) or to
the relative iron deficiency that occurs in the macrophages
in the presence of the C282Y sequence variant, and offers
a possible protection against many virulent species of
bacteria that multiply mainly in iron-rich macrophages,
such as Mycobacterium tuberculosis and Yersinia pestis (59 ).
Although this latter theory is tantalizing, it remains to be
tested at both the molecular level and in epidemiologic
studies.
During the past few years, the understanding of the
prevalence of clinically overt C282Y-homozygous HH has
undergone a revision. In contrast to most of the earlier
studies, recent surveys involving HFE genotyping of
nonclinically selected populations found that most C282Y
homozygotes had no symptoms of disease (60–63). The
Table 2. Characteristics of the hereditary forms of iron overload.
HH Gene OMIM type Interaction Frequency Hepcidina Severityb Clinical findings
Classic HFE 1 TfR1?c Frequent 2  Clinical: Symptoms start after 4th decade. Chronic
fatigue, joint pain, impotence, infertility,
hepatomegaly, diabetes mellitus, skin
pigmentation, liver cirrhosis, decompensation
cordis, arrhythmias.
Biochemical: Increased serum TS and ferritin
concentrations.
Morphologic: Iron overload predominantly in
hepatocytes.
Inheritance: Autosomal recessive, prevalent male
expression
Juvenile
HJV-related HJV 2a Neogenin Rare 22  Clinical: Symptoms start after the 1st decade.
Abdominal pain, hypogonadotropic
hypogonadism, cardiac arrhythmias and
intractable heart failure, diminished glucose
tolerance.
Hepcidin-related HAMP 2b Ferroportin Very rare 22  Biochemical: Increased TS and ferritin
concentrations.
Morphologic: Iron overload in liver, heart,
endocrine glands, and skeletal muscle.
Inheritance: Autosomal recessive, both sexes
equally affected.
TfR2-related TFR2 3 Transferrin Very rare 2  Clinical, biochemical, and morphologic: Similar to
HFE-related hemochromatosis.
Inheritance: Autosomal recessive.
Ferroportin
disease
SLC40A1 4 Hepcidin Rare 1 ?  Clinical: Symptoms of iron overload comparable to
HFE-related hemochromatosis, mild anemia early
in life, reduced tolerance to phlebotomy.
Biochemical: Marked increase in serum ferritin
with relatively mildly increased TS.
Morphologic: Iron overload predominantly in
reticuloendothelial cells.
Inheritance: Autosomal dominant.
a2, mildly decreased; 22, strongly decreased; 1, increased.
b , mild; , moderate; , severe; , very severe.
c ?, not known.
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incomplete penetrance of the C282Y sequence variant
raises questions about the cost-effectiveness of population
screening. Instead, early case detection by family (cas-
cade) screening and increased awareness for the disease
in the presence of symptoms that are consistent for HH is
more likely to have a significant effect (64–66).
HFE genotypes other than C282Y homozygosity rarely
cause clinically significant iron overload [reviewed in Ref.
(67 )]. C282Y heterozygotes usually do not develop iron
overload unless they have associated conditions, such as
environmental factors (alcohol, viruses, hepatic disease)
or variant forms of other genes (see below). These C282Y
carriers not only have increased mean TS and ferritin
concentrations compared with their wild-type counter-
parts, but also increased concentrations of non–trans-
ferrin-bound iron (NTBI) (68 ). NTBI is thought to be the
potentially toxic form of iron responsible for tissue dam-
age in cases of iron overload (Fig. 2) (69, 70). The plasma
concentration of NTBI, which is a rather unknown species
of iron, highly correlates with that of TS in HH patients
(71 ).
Case–control studies on the relationship of the C282Y
heterozygous genotype with diseases, however, have not
consistently supported heterozygosity as a risk factor for
diabetes, arthritis, cancer, liver disease, and cardiovascu-
lar disease [reviewed in Ref. (72 )].
A particular group of HFE genotypes consists of per-
sons who are compound heterozygous for C282Y and
H63D. These individuals have been described as being at
higher risk to develop iron overload, but in a generally
much milder form than in C282Y homozygotes (73, 74).
However, given the fact that the clinical penetrance of
C282Y homozygosity is very low (62 ), compound het-
erozygotes with clinical disease will be scarce. A third
sequence variant, S65C, with an allele frequency as low as
1.6%–2.0%, was found to exert a consistent but small
effect on serum iron indices, particularly when present in
combination with other HFE genotypes, such as C282Y
and H63D (75–77). However, to date there are no con-
vincing data that S65C is associated with HH. Therefore,
there is insufficient evidence to include testing for S65C to
confirm the presence of HH in patients with increased
serum iron indices. Other HFE sequence variants of
clinical relevance are rare, and most of them are private
(78 ).
The molecular function of HFE in iron metabolism has
long been attributed to the crypt hypothesis (79, 80).
According to this widespread view, the HFE protein
linked to transferrin receptor 1 (TfR1) in the duodenal
crypt stem cell is the sensor of total body iron, aimed at
programming the expression of iron transporters in ab-
sorptive cells in the villi. In this model, the relative iron
deficiency of mature absorptive enterocytes and increased
intestinal absorption at the apical membrane of the en-
terocyte are attributed to abnormal interaction between
TfR1 and mutant HFE in the basolateral membrane. This
theory has been opposed by the recent work of Enn’s
group (81 ), who showed that the association of HFE with
TfR1 is not essential to its function. However, it is mainly
since the discovery of hepcidin that the crypt model has
been replaced by the “hepcidin model” as the prevailing
hypothesis (Fig. 1). Sequence variations in HFE were
shown to lead to inappropriately low concentrations of
hepcidin, suggesting thatHFE is involved upstream in the
regulation of hepcidin expression (82, 83). Because hepci-
din synthesis is restricted to liver cells, this provided
strong evidence that HFE in the liver and/or macro-
phages was exerting its effects in hepatic cells and not in
crypt cells (84 ). Indeed, available data do suggest that
HFE/TfR1 in parallel to transferrin receptor 2 (TfR2) is
implicated in the iron-sensing pathway of hepatocytes
that controls hepcidin synthesis (Fig. 2D) [reviewed in
Ref. (84 )]. Taken together, it is not known yet exactly how
HFE senses body iron. Nevertheless, by controlling serum
concentrations of the proposed central iron regulator
hepcidin, HFE appears to be involved in the maintenance
of body iron homeostasis. Hepcidin has been reported to
exert this regulatory role by disrupting the function of
ferroportin, a major transmembrane iron exporter on
enterocytes and macrophages (Fig. 1) (4 ). This model fits
the hypothesis that plasma iron loading in HH stems from
inappropriately excessive release of iron not only by
enterocytes but also by hepatocytes and macrophages
(85 ). Recently, De Almeida et al. (86 ) proposed that HFE
encodes for an HLA-like molecule that has some immune-
related function. This provides molecular evidence that a
protein shown to affect iron metabolism also clearly
affects immunologic functions.
Since the identification of the hemochromatosis (HFE)
gene, remarkable developments have occurred in our
understanding of iron transport and storage molecules,
with the description of hepcidin, hemojuvelin (HJV),
TfR2, and ferroportin proteins, in which alterations can
lead to various types of HH (Table 2 and Fig. 2) (19 ).
Juvenile Hemochromatosis
Juvenile hemochromatosis shares most features with
adult hemochromatosis, but the clinical manifestations
develop earlier because intestinal iron absorption is
higher and the rate of iron accumulation is faster. Indi-
viduals with the juvenile phenotype are more likely to
present with cardiomyopathy and/or endocrine diseases,
although liver cirrhosis is also part of the syndrome.
juvenile hemochromatosis attributable to hjv
deficiency
The most common gene causing juvenile hemochromato-
sis was recently identified, mapping to the pericentro-
meric region of the long arm of chromosome 1 (Table 2)
(16 ). The gene HJV [hemochromatosis type 2 (juvenile);
also known as HFE2] encodes a newly identified protein,
called hemojuvelin (HJV), and is highly expressed in
skeletal muscle and heart and only to a limited extent in
liver (Fig. 2D) (16, 87). HJV contains a C-terminal putative
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transmembrane domain characteristic of a glycosylphos-
phatidylinositol (GPI)-linked membrane anchor. To date,
25 different sequence variants have been detected in the
HJV gene clustered in exons 3 and 4 (78, 88). The finding
of low and even unmeasurable hepcidin concentrations in
patients carrying sequence variants in the HJV-encoding
gene indicates that the protein is related to hepcidin and
not a component of a distinct pathway (16 ). This relation-
ship between HJV and hepcidin synthesis is further
strengthened by recent reports (89, 90). In short, there
appear to be 2 forms: a GPI-linked cell-associated HJV,
which may interact with a transmembrane neogenin re-
ceptor to induce changes in hepcidin synthesis in the
liver; and a soluble, circulating form derived from skeletal
muscle that can serve as an antagonist to disrupt these
interactions. It is hypothesized that the amount of shed-
ding of soluble HJV is down-regulated by increased iron
supply to the muscle or oxygen tension in the circulation.
The subsequent binding of soluble HJV to the neogenin
receptor in hepatocytes is suggested to down-regulate
hepcidin mRNA through as yet unidentified pathways
(Fig. 2D) (89, 90). These pathways need further experi-
mental confirmation; however, if confirmed, soluble HJV
could be a useful biomarker in disorders of iron metabo-
lism.
juvenile hemochromatosis attributable to
hepcidin deficiency
The first gene identified in juvenile hemochromatosis was
hepcidin antimicrobial peptide (HAMP), which encodes
hepcidin. The sequence variants reported to date, all in
the homozygous state, all cause juvenile onset of the
clinical disease (Table 2) [(15 ) and reviewed in Ref. (78 )].
Identification of the HAMP gene as being responsible for
a subset of juvenile hemochromatosis conclusively linked
hepcidin to iron metabolism in humans (12–14, 91–93).
Recent experimental data on iron accumulation in organs
of mice with disrupted SMAD4 [mothers against DPP
homolog 4 (Drosophila)] gene in the liver indicate that
much remains unknown concerning the factors and con-
dition involved in hepcidin regulation. In this latter study,
for example, the authors found that growth signals (trans-
forming growth factor-/bone morphogenetic proteins)
that are involved in diverse developmental processes also
induce hepcidin synthesis, requiring SMAD4 as a well-
known tumor suppressor gene to transcriptionally acti-
vate the hepcidin promoter (94 ).
hemochromatosis attributable to TfR2
deficiency
The gene coding for transferrin receptor 2 (TfR2) was
described in 1999 (8 ). This protein has a high degree of
homology with the classic transferrin receptor (TfR1) but
is expressed predominantly in the liver and in erythroid
precursors (Fig. 2) (95, 96). Compared with TfR1, TfR2
binds diferric transferrin with 30-fold lower affinity.
Genetic hemochromatosis linked to sequence variations in
the TFR2 gene is rare and seems, with a few exceptions, to
be clustered to families of southern European origin,
mainly from Italy and Portugal, and to families in Japan
(Table 2) (9, 97, 98). It has been suggested that in hepato-
cytes HFE/TfR1 and TfR2 act in the same or converging
pathways upstream from hepcidin. In this hypothesis,
TfR2 is thought to be a sensor of plasma transferrin
saturation in the signaling pathway that controls hepcidin
synthesis (Fig. 2D) (84, 85, 99–103). This is in line with the
low hepcidin concentrations found for patients carrying
TfR2 variants (104, 105), and a more severe HH pheno-
type when both HFE and TfR2 variants are present (106).
In general terms, clinical complications, the pattern of
liver iron storage, and the response to phlebotomy are
identical in HFE-related HH [Online Mendelian Inheri-
tance in Man (OMIM) type 1] and TfR2-related HH
(OMIM type 3; Table 2). The onset in the latter, however,
is generally somewhat earlier in adult life (107, 108).
Ferroportin Disease: The SLC40A1 Gene
Ferroportin 1 is a protein implicated in the efflux of iron
out of cells such as enterocytes or macrophages (Fig. 1 and
Fig. 2, A, C, and D) (10, 109). Sequence variants in the
SLC40A1 [solute carrier family 40 (iron-regulated trans-
porter), member 1] gene (previously called SLC11A3),
which encodes ferroportin/iron-regulated transporter
1/metal transporter-1 protein, have been demonstrated to
be linked to a dominant form of hereditary iron overload
(Table 2) (5, 11, 110). The ferroportin protein, predicted to
have several transmembrane domains, is expressed
mainly in Kupffer cells and splenic macrophages, at the
basolateral membrane of enterocytes, and to a lesser
extent in hepatocytes, where it coordinately plays the role
of iron exporter (109, 111–113). This export appears to be
tightly regulated by hepcidin to prevent either iron defi-
ciency or iron excess (114). Hepcidin was shown to bind
to ferroportin in epithelial cells and macrophages and
induces internalization and degradation of ferroportin,
thereby blocking iron export (4–6).
Several SLC40A1 sequence variants have been de-
scribed and are distributed worldwide. A common dele-
tion (162delVal), has been found in unrelated families
(78, 115, 116). Other sequence variations are private, with
the exception of the Q248H substitution, which has been
detected in populations of African descent but for which
contribution to African iron overload is a matter of debate
(117–121). Recent studies have shown that most SLC40A1
sequence variants are unresponsive to hepcidin-mediated
internalization (5, 122, 123).
Ferroportin disease has distinctive features compared
with HFE-related hemochromatosis. Young patients gen-
erally present with isolated hyperferritinemia and normal
or slightly increased TS (Table 2) (124). Marked hepatic
iron overload progressively develops, and histologically,
iron accumulates predominantly in liver macrophages
(Kupffer cells). Therapeutic phlebotomies may be poorly
tolerated and lead to IDA. Therefore, during treatment, TS
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values and hemoglobin concentration must be closely
monitored. Usually, ferroportin disease is less severe than
HFE-related hemochromatosis (124).
Since the description of the first families with ferropor-
tin disease attributable to either 162delVal and N144H
changes in SLC40A1 (11, 110), different phenotypic pre-
sentations have been noted in the SLC40A1 gene. It
appears as though there are several classes of ferroportin
variants depending on the causative ferroportin mutants.
These variants differ mainly in the extent of increase in TS
values, the tendency to (borderline) anemia, and the
distribution of iron deposits among macrophages and
hepatocytes (11, 110, 117, 122, 123, 125, 126). Recent at-
tempts to subdivide the phenotypes have led to 2 classes,
described as a loss-of-function and a gain-of-function
phenotype, respectively (126). This first classification is
based on recent publications on the in vitro behavior of
the different variants, which for this purpose is correlated
with clinical data from the numerous publications since
2001 on families carrying SCLC40A1 sequence variations
(5, 117, 122).
One of these phenotypes is consistent with a loss-of-
function hypothesis, and haploinsufficiency has been at-
tributed to mutant ferroportin (A77D, 162delVal, G490D,
and G323V) that is retained inside the cell (5, 110, 117,
122). The decrease in iron efflux causes a bottleneck in
cells that generate the largest iron flows, i.e., macrophages
involved in the recycling of iron from senescent erythro-
cytes. Thus, consistent with a disorder of pure iron
release, these patients experience iron retention, mainly in
macrophages, which leads to the combination of high
ferritin concentrations, low TS, iron-deficient erythropoi-
esis, and even mild anemia or impaired tolerance of
phlebotomy. Because the iron accumulated in macro-
phages has low toxicity, these patients rarely develop
iron-related clinical complications. The findings of high
urinary hepcidin concentrations in patients carrying the
162delVal variant might explain the internalization and
degradation of the nonmutated trans allele, which leads to
an additional decrease in intestinal iron uptake (127, 128).
On the other hand, in patients who carry other se-
quence variants (Y64N, N144D, N144H, C326Y, and
C326S), iron accumulates in the hepatocytes; these pa-
tients thus develop clinical signs of iron-induced damage,
as in classic hemochromatosis (5, 11, 117, 122, 129, 130).
This gain-of-function phenotype has been postulated to
be the consequence of hepcidin resistance of the mutated
ferroportin. As a result, an inappropriately high number
of mutant ferroportin molecules is displayed on the cell
surface, leading to increased iron efflux from enterocytes
and macrophages. This lack of regulation appears to
mimic hepcidin deficiency and to yield a phenotype
similar to HFE-related hemochromatosis, in which intes-
tinal iron absorption is increased, TS is increased, and
excess iron is deposited in hepatocytes and other tissues.
Here the presence of a surplus of iron in the circulatory
compartment may be related to better tolerance of phle-
botomies. In particular, patients with ferroportin variants
that completely obstruct hepcidin sensitivity (Y64N and
C326S) (122) exhibit a more severe phenotype, with
predominant iron overload in the hepatocytes. Dysfunc-
tion appears to be less severe in patients carrying the
N144D and N144H variants, in whom the hepcidin sen-
sitivity of ferroportin is only partially hindered and iron
accumulates in both the hepatocytes and macrophages
(117, 122, 131, 132). Hepcidin concentrations in some of
these cases with a gain-of-function phenotype are in-
creased, whereas others are normal but relatively too low
to the degree of iron loading (108).
Diagnosis of ferroportin disease is complex because it
requires that all various conditions causing isolated hy-
perferritinemia are ruled out. Ferroportin disease should
always be suspected in familial forms of hyperferritine-
mia or in sporadic cases of high ferritin in the absence of
known secondary causes, such as infection, metabolic
syndrome, inflammation, and malignancy (124, 133). Dif-
ferential diagnosis should also include familial hyperfer-
ritinemia congenital cataract syndrome (HHCS), which is
a rare disease without iron overload but with high ferritin
concentrations (134, 135); aceruloplasminemia, which
manifests predominately with neurologic symptoms
(136, 137); and the increasingly prevalent metabolic syn-
drome present in obese, hypertensive, insulin-resistant, or
dyslipidemic individuals (Table 1) (39, 43).
Because clinical data will accumulate with time and in
vitro and experimental studies in mice and humans will
be performed, it will undoubtedly become clear whether
this first classification of ferroportin disease is still useful
or needs to be adjusted based on new insights. This
classification might be of help in prescreening for diagno-
sis based on hepcidin concentrations and in determining
the prognosis and optimal treatment. To date, the experi-
ence with treatment of ferroportin disease has been lim-
ited. It is possible that treatment protocols will become
less stringent than those for the other forms of HH
because macrophage iron is less likely to cause tissue
damage and some patients suffer from impaired tolerance
of phlebotomy. Alternatively, chelation therapy might be
considered in those cases with substantial parenchymal
iron overload and low tolerance of phlebotomy.
Modifiers of Hemochromatosis Type I
The majority of C282Y-homozygous individuals will
present with abnormal iron indices (138), whereas only a
small number will manifest clinical features (60, 61, 139,
140). “Mild” genotypes such as C282Y homozygosity are
relatively susceptible to the effect of environmental and
genetic modifiers. As more modifiers are identified, our
ability to predict those C282Y-homozygous patients with
an increased risk for developing severe iron overload and,
consequently, clinical complications will improve. The
identification of more modifiers will therefore contribute
to the debate on whether population screening for HH
should be undertaken or whether alternative strategies
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should be implemented to improve early detection (140).
Among these approaches is the screening of relatives of a
clinically overt C282Y-homozygous proband (141). This
family (cascade) screening approach might appear to be
even more cost-effective after the dominant modifying
factor in the index case is identified.
The influence of factors such as excessive alcohol
intake (142, 143), viral hepatitis (144), dietary iron (145),
or body mass index in women (146) likely explains some
of this phenotypic heterogeneity in C282Y homozygosity.
The influence of modifier genes is an attractive additional
explanation. Indeed, in addition to the background mouse
strain, several genes involved in iron metabolism act as
modifiers, as shown in HFE-knockout mice (147–149).
Support for genetic modifiers also comes from several
reported cases in which patients homozygous for the
C282Y genotype and heterozygous for HAMP or HJV
variants developed more severe iron overload than in
C282Y-homozygous patients matched for age and sex
(150, 151). Similar interactions might also occur in per-
sons who are heterozygous for HJV and HAMP variants
and carry the C282Y/H63D genotype, but the evidence
for a modulatory effect on heterozygous C282Y sequence
variations appears inconsistent (150–154). Another recent
example of digenic inheritance is the juvenile phenotype
that results from compound C282Y/H63D heterozygosity
in combination with homozygous TFR2missense variants
(106).
In general, however, multiple sequence variations in
the recently identified genes involved in iron homeostasis
are rare and do not appear to explain most of the variation
in the penetrance of HFE hemochromatosis (151, 153,
155). Nevertheless, there is evidence that persons with the
Hp 2-2 sequence variant of the gene coding for the
haptoglobin protein have higher iron stores than controls
(156, 157), although this is not found consistently (158). In
addition, some centers have reported that the presence of
2 copies of the ancestral HLA haplotype on chromosome
6 leads to more iron loading. However, this could not be
confirmed by detailed analysis of chromosome 6p21.3 and
the HFE gene (155, 159).
Finally, the penetrance of C282Y homozygosity could
also be the result of multiple small additive effects that
change the classic monogenic hemochromatosis into an
oligenic or even a multifactorial disease in which homozy-
gosity for the C282Y variant is only a predisposing factor.
The OMIM Classification
The OMIM database (http://www.ncbi.nlm.nih.gov/
omim/) lists 4 types of HH, each caused by sequence
variations involving a different gene (Table 2). However,
most workers in the field of iron metabolism do not
approve with this classification because (a) it is neither
genotypic nor phenotypic, but rather a mixture of the two;
(b) it leaves no space for recently identified atypical cases
that are related to combinations of sequence variations
(106, 148–152); (c) it sets up hypothetical genes, e.g.,
HFE1, HFE2, HFE3, and so forth, when its not really a
gene family at all; and finally (d) there are also other forms
of hemochromatosis that are not included in the OMIM
classification (Table 2). Therefore, among others, Pi-
etrangelo (19 ) recently pled for a definition that is based
on the pathophysiologic entity instead of on the respon-
sible genes. Nevertheless, the associations of the various
genes with either an adult (HFE, TFR2, ferroportin) or a
juvenile onset (HJV and HAMP) are helpful in selecting
the starting point for genetic testing. If a patient also has
a marginally decreased hemoglobin, increased hepcidin,
or poorly tolerates phlebotomy, ferroportin disease
should be considered. Probably in the future hepcidin
concentrations in urine or serum might be of help in
prescreening patients with a clinical and biochemical
presentation consistent with non–HFE-related forms of
HH (a) to differentiate between the 3 additional types or
their combinations (Table 2 and Fig. 3); (b) to determine
prognosis in time; and (c) to optimize individual treat-
ment by choosing among no treatment, phlebotomy,
chelation therapy, or to treat with hepcidin agonist or
antagonists. If confirmed, urinary or serum hepcidin
concentrations might even form the basis of a revised
classification of HH.
Rare Genetic Defects of Iron Loading
The vast majority of hereditary iron overload reported to
date seems to be caused by HFE, TFR2, ferroportin, HJV,
or HAMP sequence variations. However, there are other,
more rare genetic defects that appear to lead to tissue iron
accumulation (Table 2).
In hereditary cases of iron overload in the presence of
isolated hyperferritinemia, the differential diagnosis
should include hypotransferrinemia and aceruloplas-
minemia.
Hypotransferrinemia is a rare recessive disease, char-
acterized by an extremely low transferrin concentration,
severe IDA, and iron loading of the liver and other
parenchymal organs (160, 161). Aceruloplasminemia is a
late-onset recessive disease attributable to sequence vari-
ations in the ceruloplasmin gene. Ceruloplasmin is a
copper-dependent ferroxidase that likely cooperates with
ferroportin to export iron frommacrophages, hepatocytes,
and intestinal mucosal cells (Fig. 2). The disease is char-
acterized by diabetes mellitus, iron loading of the liver
and pancreas, retinal degeneration, and neurologic signs
and symptoms attributable to stimulation of hydroxyl
radical formation by the persistent presence of Fe2 in the
circulation. Anemia is usually present early in life because
of insufficient iron supply to the erythron. The combina-
tion of low serum iron and transferrin but high serum
ferritin should raise suspicion of this disease (136, 137).
In hereditary cases of isolated hyperferritinemia in the
absence of iron overload, the presence of HHCS should be
considered. In this condition, sequence variations in the
5-untranslated region of the L-ferritin (FTL) gene can
cause increased serum ferritin (133–135, 162). The absence
Clinical Chemistry 52, No. 6, 2006 959
of an increased TS suggests that, in this syndrome, hyper-
ferritinemia is not attributable to iron overload, but to a
dysregulation of the production of L-ferritin light chain in
relation to mutations in the iron-responsive element of the
L-ferritin mRNA.
Lately, the first example of sequence variants for
SLC11A2, the gene that encodes for divalent metal trans-
porter 1 (DMT1; also known as DCT1 or NRAMP2), was
shown in a human with hepatic iron overload in the
presence of hypochromic anemia (163, 164). DMT1 is a
metal transporter that transports dietary Fe2 at the brush
border of duodenal enterocytes in concert with duodenal
cytochrome B (DCytB), a ferrireductase (Fig. 2A). DMT1 is
also responsible for the recovery of iron from recycling
endosomes during TfR-associated cellular uptake in
erythrocyte precursor cells and other cells needing iron
(Fig. 2, B and C). The human presentation surprisingly
differs from that of rodents with variant DMT1, which do
not develop iron overload but do present with severe
forms of hypochromic, microcytic anemia with dimin-
ished erythrocyte survival (165). The increased iron ab-
sorption in humans likely bypasses the DMT1 defect in
the gut and could be related to up-regulation of the
recently identified mammalian heme transporter, heme
carrier protein 1 (HCP1; Fig. 2A) (166, 167).
Defects in proteins known to be involved in iron
metabolism, such as hephaestin or DcytB, have not been
identified in humans (Fig. 2A). In addition, several new
proteins of the iron-regulatory pathways are still being
discovered, e.g., the ferrireductase 6-membrane epithelial
antigen of the prostate 3 (Steap3; Fig. 2B) (168) and the
hemoglobin deficit (hbd) sequence variation in the mouse
gene Sec15l1 (169). It is reasonable to expect that in time
previously undiagnosed defects in iron homeostasis could
be ascribed to defects in these newly identified genes.
Role of Hepcidin
Hepcidin is shown to be the principal regulator of sys-
temic iron homeostasis (Fig. 1). We will therefore elabo-
rate on the formation of hepcidin and its diagnostic
assessment in more detail. In concordance with its dual
function, hepcidin expression is modulated by systemic
iron requirements and infectious and inflammatory stim-
uli (Fig. 1). Its discovery has changed our understanding
of the pathophysiology of iron disorders (170). Hepcidin
acts as an iron hormone to control iron absorption and
macrophage iron release (Fig. 1). Recent reports indicated
that hepcidin does so by diminishing cellular iron efflux
by binding to the transmembrane iron exporter ferropor-
tin on enterocytes and macrophages and subsequently
inducing its internalization (4–6).
Hepcidin is produced by hepatocytes and is secreted
into plasma as a 25-amino acid mature form (12, 14, 171)
(Fig. 2D). In addition to the 25-amino acid form, addi-
tional amino-terminal processing events produce 2
smaller hepcidin forms of 22 and 20 amino acids, which
can be isolated from urine (14 ). In vivo studies in mice
have demonstrated that only the full-length 25-amino acid
hepcidin induces significant hypoferremia when injected
intraperitoneally (172). Recently, these findings were con-
firmed by in vitro studies from the same group that
showed that compared with the 25-amino acid hepcidin,
the truncated 22-amino acid form has greatly diminished
activity, whereas the deletion of 5 N-terminal amino
acids, in the case of 20-amino acid hepcidin, led to almost
complete loss of activity (173).
hepcidin in hemochromatosis
HH. Urinary hepcidin is extremely low or even undetect-
able in all juvenile cases of hemochromatosis studied
(Table 2) (16, 127). Similar findings of low hepatic hepci-
din RNA expression or low urinary hepcidin concentra-
tions characterize men with HFE deficiency and HFE
sequence variants (82, 174, 175) and patients with TFR2
sequence variants (104). Concentrations in ferroportin
disease appear to vary with the sequence variations in the
SCL40A1 gene and the ways they influence the activity of
the ferroportin protein. High urinary hepcidin concentra-
tions were reported for patients with the 162delVal vari-
ant. This might explain the internalization and degrada-
tion of the nonvariant trans allele, which lead to additional
decreases in intestinal iron uptake (127). In contrast,
hepcidin concentrations are within reference values in
some cases with a gain-of-function variant (108), but are
relatively too low for the degree of iron loading.
The digenic inheritance of variant HFE with variant
forms of HAMP, HJV, and TfR2, found in some patients
with clinically overt HH, might be consistent with a
synergistic effect that these encoded proteins exert on the
main regulator of iron metabolism, hepcidin (Fig. 2D).
The ratio of urinary hepcidin to serum ferritin could be
a useful index for assessing inadequate hepcidin re-
sponses to iron loading in hemochromatosis. For example,
patients with HH attributable to TfR2 variants have a low
hepcidin/ferritin ratio (104). Thus, the lack of appropriate
hepcidin response to iron loading could be a unifying
diagnostic test for all of these disorders (Fig. 3). In
addition, the hepcidin concentration could correlate with
the severity of the phenotype and determine the progno-
sis and need for stringency of the treatment protocol.
Secondary hemochromatosis. The hepcidin/ferritin ratio is
also low in several secondary syndromes of iron overload
characterized by ineffective erythropoiesis, including
thalassemia and congenital dyserythropoiesis type 1. In
pilot-scale studies, hepcidin is found to be suppressed for
both disorders, with a median hepcidin/ferritin ratio in
thalassemia syndromes that is only 5% of that of controls
(176), indicating that the erythroid iron needs appears to
be dominant over the inhibitory signals of iron stores
(80, 127, 177, 178). In addition, available data, although
limited, suggest that sickle cell anemia and hereditary
spherocytosis, both disorders in which altered erythrocyte
physiology leads to accelerated hemolysis and increased
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erythropoiesis (which implicates an increased iron de-
mand), also lead to relatively low hepcidin concentrations
(176). The above results are in line with the theory that
iron absorption is increased in a variety of refractory
anemias characterized by erythroid hyperplasia in con-
junction with ineffective erythropoiesis. Thus, even with-
out transfusions, these patients will accumulate iron.
However, most of these disorders are transfusion depen-
dent; therefore, the iron burden in these disorders is
mainly attributable to multiple transfusions. In thalasse-
mia patients, transfusion can lead to increased urinary
hepcidin concentrations after 3–4 days, most likely as a
result of relief of anemia and, thus, suppression of eryth-
ropoiesis and a decreased demand for hepatic iron (176).
Hepcidin concentrations may also predict effects on iron
absorption. In patients with hemolytic anemia receiving
erythrocyte transfusions, increasing hepcidin concentra-
tions will decrease iron absorption.
These findings highlight hepcidin as a diagnostic tool
in both hereditary and secondary forms of hemochroma-
tosis and may also contribute to the development of
innovative therapeutic interventions. Further optimiza-
tion and increased access to assays for urinary and serum
hepcidin as well as analysis of hepcidin in various forms
of hemochromatosis are needed, however, to further
enlarge our understanding of the contribution of hepcidin
in these disorders. This will be of value as a substitute for
the cumbersome procedures for detecting genetic variants
in these non–HFE-related forms of HH (Fig. 3). Addition-
ally, this might be relevant for the thalassemia syndromes,
for which there is an ongoing search for noninvasive
measures of iron burden and improved therapeutic inter-
ventions.
hepcidin in ai
AI, or anemia of chronic diseases, represents an important
and highly prevalent clinical problem. Recent studies
indicated that hypoferremia in inflammation is caused by
a cytokine-mediated (particularly interleukin-6 and -1)
increases in hepcidin production (179–182). The axis that
produces AI leads from interleukin-6 and -1 to hepcidin,
via blocking of ferroportin, to hypoferremia, and then to
AI. These findings are in line with characteristics of AI:
sequestration of iron in macrophages and hepatocytes
and decreased iron absorption, all of which decrease
plasma iron concentrations. The purpose of these events is
proposed to be to limit the availability of iron for micro-
bial growth. On the other hand, this leads to insufficient
iron for erythropoiesis, with consequent development of
anemia. Thus, the development of AI can be considered a
side effect of the hepcidin-induced hypoferremic response
to infection and inflammation.
Hepcidin is low in IDA (175, 179). The correct diagno-
sis of iron deficiency, however, is essential for successful
patient management. Nevertheless, in some patients, typ-
ically those with inflammatory problems, diagnosis can
be difficult. Measurement of ferritin is currently the most
accepted laboratory test for diagnosing body iron defi-
ciency, but persons with AI may have normal or increased
ferritin values even when iron deficient. The plasma
concentrations of iron and transferrin, however, are de-
creased (183, 184). Other markers that have been devel-
oped in recent years for this purpose include the soluble
TfR (sTfR) and new erythrocyte indices provided by
advanced hematology analyzers (185–187). The ratio of
sTfR to ferritin (R/F ratio) has even been suggested as the
gold standard. A drawback of the use of this ratio in
medical practice, however, is the lack of appropriate
standardization of the current sTfR assay (188). This
necessitates that each laboratory calibrate the R/F ratio by
quantitative phlebotomy measurements (189). Additional
studies are needed to assess whether hepcidin measure-
ments aid in the selection of patients with chronic inflam-
mation who are also iron deficient and therefore need
further investigation to explain their IDA and to guide
treatment with iron supplements.
Hepcidin Assays
Assays for hepcidin detection and quantification in
plasma or urine have not been widely available, and the
development of reagents has been hampered by technical
difficulties. The development of immunochemical meth-
ods based on the production of specific anti-hepcidin
antibodies is difficult because of the small size of hepcidin
(25 amino acids), that fact that the sequence is conserved
among animal species, and the limited availability of
antigen. Therefore, at present, only a limited number of
tools are available to investigate human hepcidin protein
production, maturation, and excretion. For serum, only
the measurement of prohepcidin is possible, by a com-
mercially available ELISA that uses antibodies directed
against amino acid residues 28–47, which encompass the
propeptide region of the 60 prohepcidin precursor (Fig.
2D) (190, 191). This propeptide is removed by proprotein
convertases, most likely during the secretion process, and
is therefore not present in the mature (bioactive), 25-
amino acid form of hepcidin that is released into the
circulation. For urine, 2 assays have been reported to
measure mature hepcidin. One of them consists of puri-
fication of hepcidin from the urine by column chromatog-
raphy, with subsequent concentration of the antigen fol-
lowed by a specific immunodot method (179). More
recently, we described a surface-enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry–based
assay on a platform provided by Ciphergen Biosystems
(175). Urinary hepcidin concentrations determined by
both methods highly correlate. Notably, only the latter
mass spectrometry-based method can distinguish be-
tween the 25-, 22-, and 20-amino acid forms of hepcidin in
urine (175). The clinical utility of hepcidin measurements
in urine was recently confirmed by the fact that urinary
hepcidin concentrations significantly correlated with he-
patic hepcidin mRNA concentrations in liver transplant
patients (192).
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The relationship between hepcidin and prohepcidin
remains controversial. One question is whether the pro-
hepcidin detected by the prohepcidin antibody actually
reflects the amount of bioactive hepcidin in serum. At
present, the biological importance of the 60-amino acid
prohepcidin in regulating iron status is not known. More-
over, it can be anticipated that the prohepcidin antibody
also detects the 35-amino acid propeptide that is released
from hepcidin by proprotein convertase-mediated pro-
cessing. In addition, it is not clear yet whether the
prohepcidin detected in serum is actively and specifically
excreted by vital liver cells or is simply the result of the
aspecific and well-known physiologic phenomenon of cell
leakage by damage or death of a small percentage of cells.
Finally, it is possible that serum concentrations of the
25-amino acid hepcidin and the 60-amino acid prohepci-
din or 35-amino acid propeptide differ through variation
in their half-lives. Experimentally, using a human endo-
toxemia model, we observed increased urine hepcidin in
the presence of invariable serum prohepcidin concentra-
tions (180). On the other hand, a report of a patient with
iron accumulation attributable to ferroportin disease
showed substantially and significantly increased serum
concentrations of prohepcidin that correlated positively
with urinary hepcidin concentrations (128). Possibly, se-
rum prohepcidin and urinary hepcidin measurements
correlate only in severe iron metabolism disorders,
whereas this correlation is absent in inflammation, in
which iron homeostasis is less severely disturbed. Never-
theless, discrepancies between body fluid concentrations
of prohepcidin and the bioactive mature forms of hepci-
din raises questions concerning the clinical utility of the
currently available prohepcidin assay. For the moment,
urinary hepcidin measurements most accurately reflect
hepatic hepcidin production.
In summary, preliminary studies indicate that hepcidin
assays clearly differentiate between relevant clinical iron
disorders such as between IDA and AI and between iron
overload attributable to multiple transfusions and ineffec-
tive erythropoiesis (Table 3). Furthermore, a hepcidin
assay might have a role as a screening test for the presence
of HH, thereby reducing the workload and costs of the
cumbersome procedures of screening for sequence varia-
tions in the multiple genes responsible for HH (Fig. 3).
Clinical and Molecular Diagnosis of Hereditary Forms of HH
The combined measurements of the serum iron concen-
tration, transferrin concentration, or total iron-binding
capacity (and calculation of the TS) and the ferritin
concentration provide a simple and reliable first assess-
ment of body iron concentrations. Once hyperferritinemia
and/or increased TS have been found, acquired causes of
increased serum iron should be excluded (Fig. 3 and Table
1). Among these are some common diseases, such as liver
diseases and diseases that are part of the metabolic
syndrome: diabetes mellitus (insulin resistance), obesity,
hypertension, and hyperlipidemia (2, 39, 42–45, 47–54,
193, 194). Obesity, for example, tends to increase ferritin,
whereas it decreases serum iron and TS in wild-type
persons of either sex (42, 47, 54). TS aids in the diagnosis
of iron overload and its origin. Normal or slightly in-
creased TS in combination with increased serum ferritin
concentrations suggest HHCS, aceruloplasminemia, or
ferroportin disease (53 ).
When iron overload is suspected and acquired causes
have been excluded, diagnosis of hereditary causes of
hemochromatosis should be considered (Table 2). Cur-
rently, a liver biopsy is used for assessment of cirrhosis,
which increases the risk for hepatocellular carcinoma, or
to identify concomitant diseases. Determination of the
hepatic iron concentration by magnetic resonance imag-
ing is increasingly recognized as a valuable diagnostic
tool in patients with increased serum iron indices (195–
199) and might be useful to establish iron overload in
those patients without a pathognomonic HFE genotype
and substantially increased ferritin concentrations (500
g/L). This technology is now available in many medical
centers and might improve the diagnostic procedure by
allowing a reliable and noninvasive assessment of hepatic
iron, provided that the proper software and calibration
techniques are used.
A search for non-HFE hereditary defects is indicated in
selected cases in the presence of confirmed iron overload
in the absence of C282Y homozygosity in the HFE gene.
A severe phenotype (severe loading at a relatively
young age) points to the presence of variant forms of
hepcidin or HJV, whereas normal or only moderately
increased TS makes the presence of ferroportin disease
more likely. The measurement of urinary hepcidin may
contribute to the differential diagnosis of the non-HFE
hereditary forms of HH, hepcidin being very low in the
presence of HJV and HAMP sequence variants, low in
case of homozygosity for TFR2 sequence variants, and
likely to be increased in ferroportin disease (Table 2). In
patients with an at-risk genotype, family screening should
be carried out by assessment of iron indices and genetic
testing. A practical approach, based on the high preva-
lence of HFE sequence variants among patients with HH
and new techniques for liver iron quantification, is pro-
posed in Fig. 3.
Thus, rational gene targeting is based on information
on clinical presentation, family history, serum iron indi-
ces, concomitant diseases, age at presentation, confirma-
tion of iron overload or presence of the HFE genotype,
and hepcidin measurements. Ongoing improvements in
Table 3. Hepcidin concentrations in the various diseases.
Increased hepcidin Decreased hepcidin
High iron stores Increased and/or ineffective
erythropoiesis
Anemia of chronic disease Iron deficiency
Ferroportin disease Classic, juvenile, and TfR2 HH
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molecular biology techniques and their automation will
further assist in efficient gene diagnosis.
Conclusions and Recommendations
Since the discovery of the HFE gene in 1996, several novel
gene defects have been detected, adding to the under-
standing of the mechanism and diversity of iron-overload
diseases. At least 4 main types of HH have been identi-
fied. Surprisingly, genes involved in HH encode for
proteins that all affect pathways centered around liver
hepcidin synthesis and its interaction with ferroportin, an
iron exporter in enterocytes and macrophages. Hepcidin
concentrations in urine are negatively correlated with the
severity of HH. Cytokine-mediated increases in hepcidin
concentrations appear to be an important causative factor
in AI, which is characterized by sequestration of iron in
the macrophage system.
For clinicians, the challenge is now to diagnose HFE-
related HH before irreversible tissue damage appears and
at the same time to distinguish HH from increasingly
common diseases that lead to only moderately increased
body iron stores, such as the metabolic syndrome. The
other challenge is to optimally use both conventional and
innovative laboratory tests to differentiate between the
various causes of iron overload.
We have described a systematic diagnostic strategy for
patients with suspected HH and for their relatives. This
includes rational targeting of the gene variations to be
screened. Such a careful approach allows correct assign-
ment of the patient’s diagnosis. This has important impli-
cations for prognosis, follow-up, and treatment of the
patient and his or her relatives. We therefore recommend
that after initial clinical and laboratory investigations and
exclusion of acquired causes of hyperferritinemia, atypi-
cal patients are send to specialized centers that can
perform investigations with an up-to-date, targeted ap-
proach. However, the strategy proposed may change in
time with advances in noninvasive techniques for the
assessment of hepatic iron and tissue damage, the avail-
ability of hepcidin measurements in both urine and se-
rum, and the identification of new key players in iron
homeostasis.
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